Man Survives Aggressive Blood Cancer, Thanks South Yorkshire Medical Staff

A man diagnosed with an aggressive form of blood cancer has expressed gratitude to medical staff in South Yorkshire for saving his life. Josh Jackson, 30, from Doncaster, received a diagnosis of acute myeloid leukaemia (AML) in 2021 and underwent a stem cell transplant from his younger brother. Mr. Jackson was granted early access to an experimental medication intended to enhance his survival prospects. He stated that he “would not be here” without the dedicated work of the Sheffield Teaching Hospitals NHS Foundation Trust. “I was convinced I wouldn’t make it past Christmas,” he said. When he was 27, the managing director received an AML diagnosis that included a molecular abnormality, which is linked to a heightened risk of relapse and a reduced survival rate. “It pulled the rug from under me – I was in tears, my girlfriend was in tears,” he said. Following a successful course of chemotherapy at the Royal Hallamshire Hospital, he achieved remission, though he remained reliant on daily blood and platelet transfusions. His cancer recurred prior to the scheduled stem cell transplant. “My doctors were incredible and said they would do everything for me, but the stats were poor,” he said. The transplant proceeded as scheduled, yet his overall prognosis continued to be uncertain. Specialists at the trust administered the drug sorafenib to Mr. Jackson, with the expectation that it could enhance his survival prospects. This drug had previously been utilized to assist in stabilizing the condition of individuals suffering from kidney and liver cancer. Three years subsequent to his stem cell transplant, Mr. Jackson has remained free of cancer. “AML was historically a death sentence and my genetics were the worst possible,” he said. “The haematology team have kept me alive in every sense – not just the treatment, but the emotional support they give as well – I would not be here without them.” Mr. Jackson has resumed his professional activities, although he is no longer able to travel internationally because of his compromised immune system. Furthermore, he can no longer engage in certain hobbies, including working in theatre or piloting an aircraft, an activity he pursued recreationally as a licensed pilot. Nevertheless, he affirmed his commitment to maintaining a positive outlook, stating: “I appreciate life more than I used to.” “My now-wife, Chloe, is incredibly supportive, my family is supportive, and my friends are incredible.” He added that the medical teams across Sheffield, Doncaster, and Rotherham have nearly become a second family to him. “There are no words to describe exactly how I feel about what they’ve done for me, I don’t think they appreciate the impact they have on our lives as patients – to us, they’re our entire lives.” “I’ve lost some of my independence, but I’ve found new ways to enjoy life, and the advances in care will help others have a fighting chance too.” Sorafenib is currently recommended as a treatment for other patients with Mr. Jackson’s specific type of blood cancer who are undergoing a stem cell transplant. Dr. Alexandros Kanellopoulos, a consultant at the trust, stated: “We are delighted to have played a leading role in bringing this life-extending drug to patients.” “Treatment options for AML have remained largely unchanged for the last 30 years, so it is great to see game-changing therapies coming on board.”